Skip to content
  • Home
  • Media
  • News
  • LEO Pharma appoints Elisabeth Svanberg new member of its Board of Directors

LEO Pharma appoints Elisabeth Svanberg new member of its Board of Directors

Ballerup, June 28, 2022 – LEO Pharma today announced the appointment of Elisabeth Svanberg – MD, PhD – as new member of its Board of Directors.
Elisabeth Svanberg currently serves as member of the Board of Directors at Amolyt SA, Galapagos SA and Egetis Therapeutics AB. Since 2016 she has served as Chief Development Officer at Ixaltis SA and since 2020 as Chief Medical Officer at Kuste Biopharma. She has previously held global positions with Janssen Pharmaceuticals (a Johnson & Johnson company), Bristol-Myers Squibb and MERCK-SERONO.

- Elisabeth Svanberg brings extensive biotech and pharmaceutical experience from a multinational environment, that will be of great value for LEO Pharma in setting direction for launching new innovative treatments on the global market and in creating future growth. I look much forward to working together with Elisabeth going forward, said Jesper Brandgaard, chairman of the Board of Directors at LEO Pharma.

Elisabeth Svanberg has demonstrated success in product development in different therapeutic areas and development phases regulated by both FDA, EMA, CFDA and PMDA. She is recognized for successfully translating strategic goals into practical implementation by establishing high performing cross-functional teams in global networks and championing collaboration across functions to accelerate business results

- LEO Pharma is at a very exciting time of its development going from a traditional pharmaceutical company to a globally focused player in the innovative biotech space. It is an exciting time to join the Board of Directors and I look forward to contribute to paving the way for future success, said Elisabeth Svanberg.

Elisabeth Svanberg is Associated Professor of Surgery and holds a MD (MD License 1990) and a PhD in Surgical Sciences from University of Gothenburg, Sweden.

About LEO Pharma


LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world. In 2021, the company generated net sales of DKK 9,957 million.



Henrik Heskjaer

Director, Global External Communications
Tel: +45 3140 6180